ALアミロイドーシスの世界市場レポート 2025年

ALアミロイドーシスの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR13.0％で57億4,000万米ドルに成長します。予測期間中に予想される成長は、血球DNAの突然変異の増加、ヘルスケアインフラの拡大、多発性骨髄腫の罹患率の増加、併用療法の導入、大量化学療法の使用の増加などの要因によってもたらされます。この期間の主な動向としては、診断技術の発展、ドラッグデリバリーの技術革新、血液検査の改善、標的療法の開発、診断における人工知能（AI）の統合などが挙げられます。

血漿細胞障害の罹患率の上昇は、ALアミロイドーシス市場の成長を促進すると予想されます。形質細胞障害は、異常な形質細胞が過剰または不規則な抗体を産生し、臓器障害を引き起こす可能性がある疾患です。高齢化、平均寿命の伸び、診断技術の進歩などの要因が、これらの疾患の発生率の増加に寄与しています。形質細胞障害に起因するALアミロイドーシスは、特に異常な軽鎖タンパク質の過剰産生から生じる。これは、臓器や組織におけるアミロイド沈着物の蓄積につながり、形質細胞異常症の影響をさらに悪化させる。例えば、2024年8月、米国がん協会（ACS）は、2024年に約3万5,780人の多発性骨髄腫の新規症例が診断され、そのうち男性が1万9,520人、女性が1万6,260人と予測され、男性7,020人、女性5,520人を含む約1万2,540人の死亡が予測されると報告しました。その結果、形質細胞疾患の有病率の増加がALアミロイドーシス市場の拡大を牽引しています。

ALアミロイドーシス市場の各社は、治療効果と患者の転帰を高めるため、次世代B細胞成熟抗原（BCMA）指向性CAR T細胞療法などの革新的な治療法の開発に注力しています。BCMA指向性CAR T細胞療法は、特に多発性骨髄腫において、がん細胞表面のBCMAを標的として攻撃するように患者のT細胞を改変する先進的な免疫療法です。例えば、2023年9月、米国のバイオ医薬品会社であるイミックス・バイオファーマ社は、生命を脅かす血液疾患ALアミロイドーシスの治療を目的とした次世代CAR-T細胞療法であるNXC-201の承認を米国食品医薬品局（FDA）から取得しました。NXC-201は臨床試験で有望な結果を示しており、血液学的奏効率は100％で、これまでの治療に反応しなかった患者でも臓器が改善しました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ALアミロイドーシス PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のALアミロイドーシス市場：成長率分析
• 世界のALアミロイドーシス市場の実績：規模と成長, 2019-2024
• 世界のALアミロイドーシス市場の予測：規模と成長, 2024-2029, 2034F
• 世界ALアミロイドーシス総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のALアミロイドーシス市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 支持療法
• 手術
• 幹細胞移植
• 標的療法
• 世界のALアミロイドーシス市場薬物によって、実績と予測, 2019-2024, 2024-2029F, 2034F
• トランスサイレチン輸送阻害剤
• 免疫調節薬
• モノクローナル抗体
• プロテアソーム阻害剤
• その他の薬物
• 世界のALアミロイドーシス市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内
• オーラル
• 世界のALアミロイドーシス市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のALアミロイドーシス市場化学療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 従来の化学療法剤
• 高用量化学療法
• 世界のALアミロイドーシス市場支持療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 疼痛管理
• 臓器特異的支持療法（心臓、腎臓）
• 世界のALアミロイドーシス市場、手術の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 臓器移植
• 減量手術
• 世界のALアミロイドーシス市場幹細胞移植の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 自家幹細胞移植
• 同種幹細胞移植
• 世界のALアミロイドーシス市場標的療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• プロテアソーム阻害剤
• キナーゼ阻害剤

第7章 地域別・国別分析

• 世界のALアミロイドーシス市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のALアミロイドーシス市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ALアミロイドーシス市場：競合情勢
• ALアミロイドーシス市場：企業プロファイル
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim International GmbH
• Astellas Pharma Inc.
• Genmab A/S
• Alexion Pharmaceuticals Inc.
• Alnylam Pharmaceuticals Inc.
• Prothena Corporation plc
• BridgeBio Pharma Inc.
• Sorrento Therapeutics Inc.
• Ionis Pharmaceuticals Inc.
• Ultromics Ltd
• Neurimmune AG
• Immix Biopharma Inc.
• Oncopeptides AB
• Attralus Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ALアミロイドーシス市場2029：新たな機会を提供する国
• ALアミロイドーシス市場2029：新たな機会を提供するセグメント
• ALアミロイドーシス市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

AL Amyloidosis is a rare and serious condition where abnormal proteins, known as light chains, are produced by plasma cells in the bone marrow. These light chains misfold and form amyloid fibrils, which then accumulate in various organs and tissues, impairing their function. The heart, kidneys, liver, and nervous system are commonly affected. Symptoms depend on the organs involved but often include fatigue, swelling, shortness of breath, numbness, and organ dysfunction.

The main treatment options for AL amyloidosis include therapies such as chemotherapy, supportive care, surgery, stem cell transplants, and targeted therapy. Chemotherapy uses potent drugs to target amyloid deposits, with the goal of reducing symptoms and improving survival. These drugs include transthyretin transport inhibitors, immunomodulatory drugs, monoclonal antibodies, and proteasome inhibitors. They can be administered intravenously or orally. In terms of distribution, these treatments are typically available through hospital pharmacies, retail pharmacies, and online pharmacies, ensuring patients can access the medications based on their needs and convenience.

The AL amyloidosis market research report is one of a series of new reports from The Business Research Company that provides AL amyloidosis market statistics, including the AL amyloidosis industry global market size, regional shares, competitors with the AL amyloidosis market share, detailed AL amyloidosis market segments, market trends, and opportunities, and any further data you may need to thrive in the AL amyloidosis industry. This AL amyloidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The AL amyloidosis market size has grown rapidly in recent years. It will grow from $3.11 billion in 2024 to $3.52 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth during the historic period can be attributed to increasing awareness among healthcare providers about AL amyloidosis, a rising incidence of the condition, the aging population, the expansion of diagnostic centers, and advancements in cardiac imaging.

The AL amyloidosis market size is expected to see rapid growth in the next few years. It will grow to $5.74 billion in 2029 at a compound annual growth rate (CAGR) of 13.0%. The expected growth in the forecast period is driven by factors such as the rise in mutations in blood cell DNA, the expansion of healthcare infrastructure, a growing incidence of multiple myeloma, the introduction of combination therapies, and an increased use of high-dose chemotherapy. Key trends during this period include advancements in diagnostic techniques, technological innovations in drug delivery, improvements in blood tests, the development of targeted therapies, and the integration of artificial intelligence (AI) in diagnosis.

The rising incidence of plasma cell disorders is expected to drive the growth of the AL amyloidosis market. Plasma cell disorders are conditions in which abnormal plasma cells produce excessive or irregular antibodies, potentially causing organ damage. Factors such as an aging population, increased life expectancy, and advancements in diagnostic technologies are contributing to the increasing incidence of these disorders. AL amyloidosis, which results from plasma cell disorders, specifically arises from the overproduction of abnormal light chain proteins. This leads to the accumulation of amyloid deposits in organs and tissues, further exacerbating the effects of plasma cell dyscrasias. For example, in August 2024, The American Cancer Society (ACS) reported that around 35,780 new cases of multiple myeloma are expected to be diagnosed in 2024, with 19,520 in men and 16,260 in women, and approximately 12,540 deaths projected, including 7,020 men and 5,520 women. As a result, the growing prevalence of plasma cell disorders is driving the expansion of the AL amyloidosis market.

Companies in the AL amyloidosis market are focusing on developing innovative therapies, such as next-generation B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, to enhance treatment efficacy and patient outcomes. BCMA-directed CAR T-cell therapy is an advanced immunotherapy that involves modifying a patient's T cells to target and attack BCMA on the surface of cancer cells, particularly in multiple myeloma. For instance, in September 2023, Immix Biopharma Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for NXC-201, a next-generation CAR-T cell therapy for the treatment of the life-threatening blood disorder AL amyloidosis. NXC-201 has shown promising results in clinical trials, with a 100% hematologic response rate and organ improvements in patients who had not responded to previous treatments.

In November 2024, Stand Up To Cancer (SU2C), a US-based non-profit organization, partnered with Johnson & Johnson Inc. to advance research on novel treatments for AL amyloidosis. This collaboration aims to explore the combination of teclistamab and daratumumab as a treatment for AL amyloidosis, a rare and challenging disease, to improve therapeutic options for affected patients. Johnson & Johnson Inc., a US-based healthcare company, specializes in providing treatments for AL amyloidosis.

Major players in the AL amyloidosis market are Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Genmab A/S, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Prothena Corporation plc, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Ionis Pharmaceuticals Inc., Ultromics Ltd, Neurimmune AG, Immix Biopharma Inc., Oncopeptides AB, and Attralus Inc.

North America was the largest region in the AL amyloidosis market in 2024. The regions covered in AL amyloidosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the AL amyloidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The AL amyloidosis market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, monitoring and follow-up services, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The AL amyloidosis market also includes sales of proteasome inhibitors, monoclonal antibodies, diagnostic tests, and supportive care products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

AL Amyloidosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on al amyloidosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for al amyloidosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The al amyloidosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Chemotherapy; Supportive Care; Surgery; Stem Cell Transplant; Targeted Therapy
• 2) By Drugs: Transthyretin Transport Inhibitor; Immunomodulatory Drugs; Monoclonal Antibodies; Proteasome Inhibitors; Other Drugs
• 3) By Route Of Administration: Intravenous; Oral
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Chemotherapy: Conventional Chemotherapy Agents; High-Dose Chemotherapy
• 2) By Supportive Care: Pain Management; Organ-specific Supportive Care (Cardiac, Renal)
• 3) By Surgery: Organ Transplantation; Debulking Surgery
• 4) By Stem Cell Transplant: Autologous Stem Cell Transplant; Allogeneic Stem Cell Transplant
• 5) By Targeted Therapy: Monoclonal Antibodies; Proteasome Inhibitors; Kinase Inhibitors
• Companies Mentioned: Johnson & Johnson; AbbVie Inc.; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. AL Amyloidosis Market Characteristics

3. AL Amyloidosis Market Trends And Strategies

4. AL Amyloidosis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global AL Amyloidosis Growth Analysis And Strategic Analysis Framework

• 5.1. Global AL Amyloidosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global AL Amyloidosis Market Growth Rate Analysis
• 5.4. Global AL Amyloidosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global AL Amyloidosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global AL Amyloidosis Total Addressable Market (TAM)

6. AL Amyloidosis Market Segmentation

• 6.1. Global AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Supportive Care
• Surgery
• Stem Cell Transplant
• Targeted Therapy
• 6.2. Global AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Transthyretin Transport Inhibitor
• Immunomodulatory Drugs
• Monoclonal Antibodies
• Proteasome Inhibitors
• Other Drugs
• 6.3. Global AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Oral
• 6.4. Global AL Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global AL Amyloidosis Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conventional Chemotherapy Agents
• High-Dose Chemotherapy
• 6.6. Global AL Amyloidosis Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pain Management
• Organ-specific Supportive Care (Cardiac, Renal)
• 6.7. Global AL Amyloidosis Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Organ Transplantation
• Debulking Surgery
• 6.8. Global AL Amyloidosis Market, Sub-Segmentation Of Stem Cell Transplant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autologous Stem Cell Transplant
• Allogeneic Stem Cell Transplant
• 6.9. Global AL Amyloidosis Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Proteasome Inhibitors
• Kinase Inhibitors

7. AL Amyloidosis Market Regional And Country Analysis

• 7.1. Global AL Amyloidosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global AL Amyloidosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific AL Amyloidosis Market

• 8.1. Asia-Pacific AL Amyloidosis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China AL Amyloidosis Market

• 9.1. China AL Amyloidosis Market Overview
• 9.2. China AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India AL Amyloidosis Market

• 10.1. India AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan AL Amyloidosis Market

• 11.1. Japan AL Amyloidosis Market Overview
• 11.2. Japan AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia AL Amyloidosis Market

• 12.1. Australia AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia AL Amyloidosis Market

• 13.1. Indonesia AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea AL Amyloidosis Market

• 14.1. South Korea AL Amyloidosis Market Overview
• 14.2. South Korea AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe AL Amyloidosis Market

• 15.1. Western Europe AL Amyloidosis Market Overview
• 15.2. Western Europe AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK AL Amyloidosis Market

• 16.1. UK AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany AL Amyloidosis Market

• 17.1. Germany AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France AL Amyloidosis Market

• 18.1. France AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy AL Amyloidosis Market

• 19.1. Italy AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain AL Amyloidosis Market

• 20.1. Spain AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe AL Amyloidosis Market

• 21.1. Eastern Europe AL Amyloidosis Market Overview
• 21.2. Eastern Europe AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia AL Amyloidosis Market

• 22.1. Russia AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America AL Amyloidosis Market

• 23.1. North America AL Amyloidosis Market Overview
• 23.2. North America AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA AL Amyloidosis Market

• 24.1. USA AL Amyloidosis Market Overview
• 24.2. USA AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada AL Amyloidosis Market

• 25.1. Canada AL Amyloidosis Market Overview
• 25.2. Canada AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America AL Amyloidosis Market

• 26.1. South America AL Amyloidosis Market Overview
• 26.2. South America AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil AL Amyloidosis Market

• 27.1. Brazil AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East AL Amyloidosis Market

• 28.1. Middle East AL Amyloidosis Market Overview
• 28.2. Middle East AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa AL Amyloidosis Market

• 29.1. Africa AL Amyloidosis Market Overview
• 29.2. Africa AL Amyloidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa AL Amyloidosis Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa AL Amyloidosis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. AL Amyloidosis Market Competitive Landscape And Company Profiles

• 30.1. AL Amyloidosis Market Competitive Landscape
• 30.2. AL Amyloidosis Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. AL Amyloidosis Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceutical Company Limited
• 31.2. Boehringer Ingelheim International GmbH
• 31.3. Astellas Pharma Inc.
• 31.4. Genmab A/S
• 31.5. Alexion Pharmaceuticals Inc.
• 31.6. Alnylam Pharmaceuticals Inc.
• 31.7. Prothena Corporation plc
• 31.8. BridgeBio Pharma Inc.
• 31.9. Sorrento Therapeutics Inc.
• 31.10. Ionis Pharmaceuticals Inc.
• 31.11. Ultromics Ltd
• 31.12. Neurimmune AG
• 31.13. Immix Biopharma Inc.
• 31.14. Oncopeptides AB
• 31.15. Attralus Inc.

32. Global AL Amyloidosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The AL Amyloidosis Market

34. Recent Developments In The AL Amyloidosis Market

35. AL Amyloidosis Market High Potential Countries, Segments and Strategies

• 35.1 AL Amyloidosis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 AL Amyloidosis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 AL Amyloidosis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer